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“Insanity is doing the same thing over and over again and expecting a different result.”
Albert Einstein
PRECISION ONCOLOGY: GENETIC THERAPY AND STANDARD
TREATMENTS
Precision oncology refers to a systematic assessment of cancer, from genomics to translational
applications. Its relevance depends particularly on evidences of tumor heterogeneity: no two
cancers are the same, and often in two subjects can behave very differently. We tend to consider
heterogeneity manifested at the clinical level, but indeed it starts at the genetic level. Roughly
speaking, cancer arises in most of the cases from a group of mutated genes, in particular altered
oncogenes and tumor suppressors that cooperate to promote tumor progression. Driven by the
altered genes, the pathological behavior of tumor tissue follows. Because for the same tumor the
oncogenes can significantly vary from patient to patient, an ideal assessment of genomic alterations
at an individual basis will turn to the development of ad hoc genetic therapies removing the primary
cause of the disease. However, the implementation of genetic therapies is still far from representing
clinical routine.
Common therapies to treat solid tumors consider symptoms and are aimed at blocking the
disease progression by killing any single cancer cell. They consist of a combination of (a) Surgical
resection of the neoplastic mass, followed by (b) Radiation therapy to sterilize the surgical bed
and tumor border, and (c) Systemic chemotherapy, if necessary. Thus, on one hand a local control
of the disease is needed, but with chemotherapy on the other end the goal becomes to prevent
the dissemination of malignant cells into other organs, and consequently avoid the formation of
metastases. Each combination of these three modalities ultimately tries to avoid any possibility of
replication. In particular, the target of radiation treatment is the cellular DNA that can be broken
by means of direct or indirect radiation effects (Lomax et al., 2013). Instead, chemotherapy targets
specific processes underlying the regulation of tumor growth through biomarkers that identify
tumor cells. In both therapeutic contexts, the biological rationale hypothesizes higher toxicity to
malignant than to normal cells.
Two weaknesses emerge from this approach: (a) The differences between tumor and healthy
cells may be not so significant to avoid damage to healthy tissue and (b) The heterogeneity of
tumor phenotypes is not allowing development of absolute target-specific drugs. This is the case
for example for a class of anti-angiogenic drugs that target the vascular endothelial growth factor
(VEGF) with the aim to avoid the formation and development of new vessels. Recently, it has
been demonstrated that VEGF is expressed only in smaller vessel and not in the more mature and
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larger vessels (Nagy and Dvorak, 2012). Therefore, this kind of
drug affects only partially the tumor vascular network, reducing
the overall effectiveness.
PHYSIOLOGICAL MAPS: DECIPHERING
COMPLEXITY
The idea of identifying common biomarkers, or a restricted
group of them shared between all types of tumors, has inspired
oncological research since the beginning. While this goal has
not been achieved, research in this direction has highlighted two
main features of tumor behavior: heterogeneity and uncertainty.
Heterogeneity may find in some cases a multitude of
causes beyond clonal evolution or environmental differences,
generating functional diversity influencing response to therapy
and prognosis, and determining uncertainty with regards to
both biological and technological factors (Magee et al., 2012).
Overall, the two features have translated into complexity which
has drastically limited the discovery impact of efficient drugs.
Advances toward deciphering complexity have involved
quantification bymodern diagnostic imaging technique routinely
used in clinics, say Magnetic Resonance Imaging, Positron
Emission Tomography, Computer tomography, and Ultrasound.
These allow the acquisition of many features related with tumor
development, and suggest progress in quantitative imaging
(Mountz et al., 2014). The metabolic activity of tumors can
be mapped following glucose, oxygen, and free fatty acids
consumptions, which constitute the major source of energy that
cells need for replication. In turn, we can have a complete
evaluation of the vascular network architecture, physiology,
and its hierarchical connections with the healthy counterpart.
Furthermore, it is possible to determine the state of the tumor
microenvironment, which is responsible for tissue invasion and
metastasis formation. A great innovation of modern diagnostics
is the possibility to monitor dynamic physiological process in
3D-mode with a resolution reaching microscopic structure. This
means that it has become possible to determine not only the
average stage of the tumor, but to draw a detailedmap of its stages
at a microscopic scale.
Physiological maps are the key to explore complexity,
by inspecting the interactions occurring inside and outside
the cancer tissue. Intuitively, the tumor is seen as a group
of microscopic elements organized in macroscopic structures
interacting together and with the host organ. Therefore, we can
model the tumor as a complex network where the nodes are
the microscopic elements that are connected together on the
basis of their physiological behavior (Dominietto et al., 2015).
Nodes that behave similarly form macroscopic structures, or
clusters, in turn interacting between them (intra-cluster), and
with the surrounded healthy tissue. Figure 1 offers a general
and personalized view of the novel approach. The bottom
panel establishes a correspondence between image and network
domains through markers of proliferative regions.
“...In the era of internet, the real knowledge does
not come from the amount of information we are able to
process/store, but from the number of connections we are able to
establish among them.”
Somewhere in the web
BIOMARKERS, IMAGING BIOMARKERS,
DIGITAL BIOMARKERS: ROLE IN
PRECISION ONCOLOGY
Biomarkers represent a fundamental aspect of cancer research,
and are used to detect cancer or direct cancer therapy. However,
both the molecular nature and the functional architecture of
cancer are incredibly sophisticated and coordinated, revealing
interactions with immune system response, microenvironment,
metabolism, life style, nutrition, etc., which translate into a
myriad of complex signals hard to be accounted for. Similarly,
this high complexity is reflected into the need for multimodal
imaging combining a variety of features bringing additional
prediction power to molecular and functional measures. This
data complementarity paves the way for new quantifications
and models, mapping information from cells to voxels in a
multiscale inference approach ranging from macroscopic scale
(morphological features) to mesoscopic scale (cellular level)
and finer scales (imaging to investigate metabolism, stress
response, adaptation etc.; Yankeelov et al., 2013). Imaging
biomarkers build robust measures and lead clinical decisions.
Being non-invasive, imaging allows repeated measurements
over time thus capturing patient-, tissue-, or tumor specific
heterogeneity and inspecting the microenvironment under
both stationary and non-stationary (perturbed) conditions
(Farwell et al., 2015). This explains why molecular imaging
has a relevant role as a predictive biomarker and as an
early indicator of response to therapy (Mankoff et al.,
2014).
Networks allow in principle to develop patient specific
tumor models based on the measured pathophysiological maps
(Dominietto and Capobianco, 2016). While many network
metrics may be in principle established to extract information
about the cancer system under study, most networks explain
relationships between bioentities by a few standard metrics
(Roy, 2014). The specific metric underlying the topology and
dynamics of such networks can be then used for two distinct
aims in cancer research. First, to identify the critical nodes
that when targeted by a drug, may cause the collapse of
the network (catastrophic effects). This may explain cancer
dynamics linked to disruption of metastatic and resistance
mechanisms, etc. Second, to build digital biomarkers constituting
the fingerprints of specific tumors. In this case, one must
identify a variety of cancer features which call for measurement
and integration. In particular, it is crucial to indicate how
drugs contribute to such next generation of markers. Figure 1
(bottom) shows an example of digital biomarkers, indicating
high proliferative regions subject to mapping between image
and network domains. These markers highlighted as red nodes
were determined by means of the metrics performed on the
network, and also directly on the medical image to prioritize
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FIGURE 1 | Precision oncology advances. From imaging biomarkers to network quantifications and modeling, toward new patient stratifications and clinical trials
(top). Example of a clinical application in a patient with brain tumor (bottom). Sagittal and axial MRI images showed the presence of highly heterogenic glioblastoma.
Metrics readout performed in the network domain has hierarchically classified proliferative regions through a gradient, from red spots corresponding to high
proliferation rate, to light blue identifying low proliferation rate. As a result, we have mapped four most proliferating regions with red nodes in the network from the MRI
image voxels (indicated by yellow arrows). Not only this establishes inter-domain correspondence, but also emphasizes additional red nodes as supplemental network
interactions, useful for predictive purposes.
delivery treatments as ionizing radiation and drugs to such
locations.
IMPACTS ON TARGETED CANCER
THERAPY
Personalized cancer therapy is strictly associated with precision
oncology, in turn highly dependent on biomarkers. Among
these, imaging biomarkers are destined to be central due to
several unique properties, especially the ability to examine in
vivo the tumor microenvironment in perturbed or unperturbed
state, including of course early and follow-up stages of response
to therapy. This step is to be developed further in terms of
quantification of measurements, validation of data acquisition,
statistical methods for image quality and reliability of evidences,
and standardization of digital records. Enabling newly designed
qualitative and quantitative protocols, both for the detection
and classification of tumor type and stage, will make substantial
impacts on clinical decision making regarding patients selection.
Clinical imaging is thus expected to be central in future
patient-specific cancer therapies and for drug efficacy assessment
(Gatenby et al., 2013).
Looking forward, new patient stratifications based on
increased and diverse biomarkers (biomarkers varieties) will have
a dramatic impact in the design and development of clinical
trials. Among the next generation of biomarkers, digital ones
refer to physio-pathological and behavioral conditions that are
not considered in standard or traditional ways, depending on
newmedical devices, apps frommobile technologies, etc. The role
of digital biomarkers is to elucidate significance of factors such as
lifestyle, nutrition, wellness, environment, etc. such that they can
be distinguished from confounders.
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The correct classification of the disease and the personalized
treatment will restrict the variability emerging from subject
heterogeneity. Patients with a specific tumor will be cured
with specific treatment. Such aspect will drastically improve
the robustness of multicentric trials that usually suffer of non-
homogeneity issues. Moreover, the aim of therapy follow-up
will not be confined to the simple macroscopic determination
of tumor geometry as volume and mass indicators. The new
biomarkers will offer the possibility to evaluate the regression
of the disease at a pathophysiological level, allowing the
modification of the therapy “on the fly” and the calibration
of the dose preventing unnecessary side effects. This is a key
aspect as currently most clinical trials offer a randomized
approach delivering snapshots of treatments effectiveness, on
average. Instead, optimization for progressive and recurring
diseases requires a sequential clinical decision approach, over
time and space, both dimensions being useful to monitor
changes in patient’s profile, i.e., biomarker characteristics,
genetic profiles and medical histories, and response to
treatment.
BIG DATA
In healthcare, images, biological/genetic data, clinical records,
results of genetic test and other diagnosis, and biometric profiles
are increasingly generated and need to be stored as electronic
health records (EHRs) whose volume, variety and velocity are
known challenges. Scalable big data tools need integration with
analytical methods to enable decision support clinical systems
to become routine and (i) Improve disease management; (ii)
Harmonize validations of medical treatments and responses to
therapies; (iii) Focus on risk prediction and prevention. The
bottleneck is clearly the interoperability that can be achieved
when facing heterogeneity and diversity of data, in turn affecting
their complete accessibility and usability for scopes of knowledge
discovery and prediction.
CONCLUDING REMARKS
In this Opinion, we have expressed a few key points, summarized
below:
• Medical imaging is already a key component in
personalized medicine, but quantification and representation
improvements are needed for superior precision.
• Molecular biomarkers will be supported by imaging and digital
biomarkers, with impact on decisions referred to choice of
treatment and assessment of response to it.
• Prevention relying on newly conceived screening programs
will be more effective due to the better monitoring and
prediction induced by digital medicine.
• Clinical trials will become more dynamically optimized by the
means of clinical decision support systems.
Precision Oncology is what we have discussed and much more.
Currently, the field is undergoing a major change also due to
the switch from microarrays to high-throughput sequencing,
which has allowed a wider and in-depth analysis of genomes,
transcriptomes, epigenomes, etc. Imaging has remained a bit
lateral to such developments, despite the tremendous impact of
technology and the relevance especially in clinical diagnostics and
therapy assessment. Looking at the genetic layers of information
in an integrated way and predictively with imaging, will increase
our understanding of phenotypic alterations, and influence both
response to therapy and prognosis.
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